D. E. Shaw & Co., Inc. Sage Therapeutics, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $823,200 - $1.19 Million	-15,000 Reduced 60.0%	10,000 $568,000
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $1.18 Million - $1.95 Million	-45,300 Reduced 64.44%	25,000 $1.04 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $2.68 Million - $4.91 Million	-30,000 Reduced 29.91%	70,300 $11.2 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $409,700 - $698,550	5,000 Added 5.25%	100,300 $9.61 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $7.06 Million - $8.84 Million	50,300 Added 111.78%	95,300 $14.9 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $2.28 Million - $2.88 Million	15,000 Added 50.0%	45,000 $7.25 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $1.84 Million - $2.66 Million	30,000	30,000 $1.87 Million

221

49.6M

241K

587K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $516M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.